Blog

Whether you feel reborn—or even just a little bit reset—at the start of a new year, consider making your mental health a priority in 2024. Why? “Because that’s the gateway to everything else,” says Guy Winch, a clinical psychologist, author of Emotional First Aid, and co-host of the Dear Therapists podcast. “It’s the linchpin that allows you to succeed or to fail.”With that in mind, we asked Winch and other experts to share the New Year’s resolutions they wish people would make in the name of mental health.1. Rethink your social-media useSpend some time reflecting on whether you’d like to continue with the same online habits in 2024, says Nedra Glover Tawwab, a therapist and author of Set Boundaries, Find Peace: A Guide to Reclaiming Yourself. (If it’s hard to stop scrolling long enough to...

The case study involved just one patient: a 20-year-old woman with severe systemic lupus erythematosus (SLE). But the study’s results were so dramatic that they appeared in 2021 in the New England Journal of Medicine. The woman received a type of cell therapy called CAR-T, which in the past has been used primarily to treat cancer. CAR-T cell therapy involves altering a patient’s immune cells so that they identify and attack problems or pathogens. In people with cancer, that attack is aimed at the diseased cells. But in the NEJM case study, the therapy was directed at the woman’s own B cells, which are thought to be a primary cause of inflammation and damage in patients with lupus. The results were astonishing. “Within one month, nearly all of her symptoms had calmed down,” says Dr. Michell...

Doctors and parents celebrated the major advances that came in 2023 to treat respiratory syncytial virus (RSV), which sends up to 80,000 children under age five to the hospital each year in the U.S. This year, the U.S. Food and Drug Administration approved two critical ways to reduce the risk of RSV in young kids: a vaccine for pregnant mothers that can protect newborns, and a drug treatment for babies under one year.In a study published in the New England Journal of Medicine, researchers report encouraging real-world data that show how effective the drug treatment, nirsevimab (brand name: Beyfortus), can be. The study, which was funded by the drug's makers Sanofi and AstraZeneca, included more than 8,000 infants in France, Germany, and the U.K. who were one year old or younger and enterin...